{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:48:22Z","timestamp":1790876902578,"version":"4.1.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1016\/j.euroneuro.2008.07.002","type":"journal-article","created":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T09:48:31Z","timestamp":1220262511000},"page":"1-13","source":"Crossref","is-referenced-by-count":29,"title":["BL-1020: A novel antipsychotic drug with GABAergic activity and low catalepsy, is efficacious in a rat model of schizophrenia"],"prefix":"10.1016","volume":"19","author":[{"given":"Yona","family":"Geffen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Nudelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irit","family":"Gil-Ad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ada","family":"Rephaeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinneret","family":"Savitsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"Klapper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilan","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert Y.","family":"Meltzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Weizman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2008.07.002_bib1","first-page":"65","article-title":"Antipsychotic drugs. Clinical pharmacokinetics of potential candidates for plasma concentration monitoring","volume":"13","author":"Balant-Gorgio","year":"1987","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.euroneuro.2008.07.002_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0893-133X(01)00225-1","article-title":"GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder","volume":"25","author":"Benes","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2008.07.002_bib3","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1017\/S1461145702002894","article-title":"The GABAergic system in schizophrenia","volume":"5","author":"Blum","year":"2002","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2008.07.002_bib4","first-page":"212","article-title":"Action of caffeine on the spontaneous motility of the mouse","volume":"158","author":"Boissier","year":"1965","journal-title":"Arch. Int. Pharmacodyn. Ther."},{"key":"10.1016\/j.euroneuro.2008.07.002_bib5","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1176\/ajp.156.2.299","article-title":"Diazepam treatment of early signs of exacerbation in schizophrenia","volume":"156","author":"Carpenter","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2008.07.002_bib6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1615\/CritRevNeurobiol.v16.i12.20","article-title":"A GABA, reelin, and the neurodevelopmental hypothesis of schizophrenia","volume":"16","author":"Caruncho","year":"2004","journal-title":"Crit. Rev. Neurobiol."},{"issue":"Suppl. 9","key":"10.1016\/j.euroneuro.2008.07.002_bib7","first-page":"25","article-title":"Pathophysiology of antipsychotic drug-induced movement disorders","volume":"65","author":"Casey","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2008.07.002_bib8","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant, (K1) and the concentration of inhibitor which causes 50 per cent inhibition, (I50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.euroneuro.2008.07.002_bib9","first-page":"493","article-title":"Appr\u00e9ciation de la catalepsie chez le rat","volume":"6","author":"Chermat","year":"1975","journal-title":"J. Pharmcol. (Paris)"},{"key":"10.1016\/j.euroneuro.2008.07.002_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1615\/CritRevNeurobiol.v16.i12.10","article-title":"A GABAergic cortical deficit dominates schizophrenia pathophysiology","volume":"16","author":"Costa","year":"2004","journal-title":"Crit. Rev. Neurobiol."},{"key":"10.1016\/j.euroneuro.2008.07.002_bib11","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.bcp.2004.07.034","article-title":"The GABA-glutamate connection in schizophrenia: which is the proximate cause?","volume":"68","author":"Coyle","year":"2004","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.euroneuro.2008.07.002_bib12","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMe058298","article-title":"The choice of drugs for schizophrenia","volume":"354","author":"Davis","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.euroneuro.2008.07.002_bib13","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.schres.2004.02.017","article-title":"GABAergic dysfunction in schizophrenia and mood disorders as reflected by decreased levels of glutamic acid decarboxylase 65 and 67\u00a0kDa and Reelin proteins in cerebellum","volume":"72","author":"Fatemi","year":"2005","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2008.07.002_bib14","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMra035458","article-title":"Schizophrenia","volume":"349","author":"Freedman","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.euroneuro.2008.07.002_bib15","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1056\/NEJMe058200","article-title":"The choice of antipsychotic drugs for schizophrenia","volume":"353","author":"Freedman","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.euroneuro.2008.07.002_bib16","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0278-5846(96)00158-3","article-title":"Dopaminergic sensitization: implications for the pathogenesis of schizophrenia","volume":"21","author":"Glenthoj","year":"1997","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2008.07.002_bib17","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.pharmthera.2005.01.007","article-title":"The human reelin gene: transcription factors (+), repressors (\u2212) and the methylation switch (+\/\u2212) in schizophrenia","volume":"111","author":"Grayson","year":"2006","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.euroneuro.2008.07.002_bib18","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00213-005-2212-8","article-title":"GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon","volume":"180","author":"Guidotti","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.euroneuro.2008.07.002_bib19","first-page":"1","article-title":"Pharmacogenomics: a path to predictive medicine for schizophrenia","volume":"7,3","author":"Gupta","year":"2006","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.euroneuro.2008.07.002_bib20","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.2165\/00003495-200464200-00003","article-title":"Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management","volume":"64","author":"Haddad","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.euroneuro.2008.07.002_bib21","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/00131746-200309000-00003","article-title":"Hyperprolactinemia and schizophrenia: mechanisms and clinical aspects","volume":"9","author":"Halbreich","year":"2003","journal-title":"J. Psychiatr. Pract."},{"key":"10.1016\/j.euroneuro.2008.07.002_bib22","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/sj.mp.4001558","article-title":"Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence","volume":"10","author":"Harrison","year":"2005","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2008.07.002_bib23","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0924-9338(02)00696-X","article-title":"Antiepileptic drugs in schizophrenia: a review","volume":"17","author":"Hosak","year":"2002","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.euroneuro.2008.07.002_bib24","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.tins.2005.04.004","article-title":"Lighting the chandelier: new vistas for axo-axonic cells","volume":"28","author":"Howard","year":"2005","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.euroneuro.2008.07.002_bib25","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1046\/j.1471-4159.2001.00154.x","article-title":"5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release","volume":"76","author":"Ichikawa","year":"2001","journal-title":"J. Neurochem."},{"key":"10.1016\/j.euroneuro.2008.07.002_bib26","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.brainres.2005.06.009","article-title":"Valproic acid potentiates both typical and atypical antipsychotic-induced prefrontal cortical dopamine release","volume":"1052","author":"Ichikawa","year":"2005","journal-title":"Brain Res."},{"key":"10.1016\/j.euroneuro.2008.07.002_bib27","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/BF00408328","article-title":"Considerations for the pre-clinical evaluation of new psychiatric drugs: a case study with phenothiazine-like tranquilizers","volume":"9","author":"Irwin","year":"1966","journal-title":"Psychopharmacologia"},{"key":"10.1016\/j.euroneuro.2008.07.002_bib28","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0361-9230(99)00025-8","article-title":"GABA-ergic neurons and the neurobiology of schizophrenia and other psychoses","volume":"48","author":"Keverne","year":"1999","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.euroneuro.2008.07.002_bib29","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0028-3908(71)90013-X","article-title":"Blood-brain barrier to H3-gamma-aminobutyric acid in normal and amino oxyacetic acid-treated animals","volume":"10","author":"Kuriyama","year":"1971","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.euroneuro.2008.07.002_bib30","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1177\/026988119901300405","article-title":"Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies","volume":"13","author":"Laruelle","year":"1999","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2008.07.002_bib31","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/nrn1648","article-title":"Cortical inhibitory neurons and schizophrenia","volume":"6","author":"Lewis","year":"2005","journal-title":"Nat. Rev., Neurosci."},{"key":"10.1016\/j.euroneuro.2008.07.002_bib32","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.euroneuro.2008.07.002_bib33","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1176\/appi.ajp.2007.06091479","article-title":"Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study","volume":"164,","author":"Mamo","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2008.07.002_bib34","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1007\/s00018-003-2108-x","article-title":"Cellular and molecular action of the putative GABA-mimetic, gabapentin","volume":"60","author":"Maneuf","year":"2003","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.euroneuro.2008.07.002_bib35","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1602\/neurorx.2.4.579","article-title":"Developing therapeutics for schizophrenia and other psychotic disorders","volume":"2","author":"Marek","year":"2005","journal-title":"NeuroRx."},{"issue":"Suppl 1","key":"10.1016\/j.euroneuro.2008.07.002_bib36","doi-asserted-by":"crossref","first-page":"S136","DOI":"10.1038\/sj.bjp.0706473","article-title":"Dopamine: the rewarding years","volume":"147","author":"Marsden","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2008.07.002_bib37","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(04)16458-1","article-title":"Schizophrenia","volume":"363","author":"Mueser","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2008.07.002_bib38","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1021\/jm7012453","article-title":"BL-1020 a mutual prodrug ester of GABA and perphenazine exhibits antischizophrenic efficacy with diminished extrapyramidal effects","volume":"51","author":"Nudelman","year":"2008","journal-title":"J Med. Chem."},{"key":"10.1016\/j.euroneuro.2008.07.002_bib55","series-title":"The Rat Brain in Stereotaxic Coordinates","author":"Paxinos","year":"1998"},{"key":"10.1016\/j.euroneuro.2008.07.002_bib39","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.bbr.2003.10.033","article-title":"The heterozygous reeler mouse: behavioural phenotype","volume":"153","author":"Podhorna","year":"2004","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.euroneuro.2008.07.002_bib40","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nrd1346","article-title":"Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia","volume":"3","author":"Roth","year":"2004","journal-title":"Nat. Rev., Drug Discov."},{"key":"10.1016\/j.euroneuro.2008.07.002_bib41","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.coph.2005.10.003","article-title":"GABA-based therapeutic approaches: GABAA receptor subtype functions","volume":"6","author":"Rudolph","year":"2006","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.euroneuro.2008.07.002_bib43","first-page":"236","article-title":"GABAergic, dopaminergic and cholinergic interactions in perphenazine-induced catatonia in rats","volume":"278","author":"Shukla","year":"1985","journal-title":"Arch. Int. Pharmacodyn. Ther."},{"key":"10.1016\/j.euroneuro.2008.07.002_bib44","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.neuropharm.2006.07.024","article-title":"CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity","volume":"52","author":"Siuciak","year":"2007","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.euroneuro.2008.07.002_bib45","first-page":"CD000203","article-title":"Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia","volume":"4","author":"Soares","year":"2004","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.euroneuro.2008.07.002_bib46","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrd1956","article-title":"Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations","volume":"5","author":"Stroup","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.euroneuro.2008.07.002_bib49","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/01.jcp.0000095349.32154.a5","article-title":"GABA and schizophrenia: a review of basic science and clinical studies","volume":"23","author":"Wassef","year":"2003","journal-title":"J. Clin. Psychopharmacol."},{"issue":"Suppl. 6","key":"10.1016\/j.euroneuro.2008.07.002_bib50","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1002\/ana.10696","article-title":"GABA, gamma-hydroxybutyric acid, and neurological disease","volume":"54","author":"Wong","year":"2003","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.euroneuro.2008.07.002_bib51","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/1073858405284360","article-title":"Regulation of cortical interneurons by neurotrophins: from development to cognitive disorders","volume":"12","author":"Woo","year":"2006","journal-title":"Neuroscientist"},{"key":"10.1016\/j.euroneuro.2008.07.002_bib52","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0893-133X(98)00112-2","article-title":"Developing a neuronal model for the pathophysiology of schizophrenia based on the nature of electrophysiological actions of dopamine in the prefrontal cortex","volume":"21","author":"Yang","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2008.07.002_bib53","doi-asserted-by":"crossref","first-page":"17154","DOI":"10.1073\/pnas.0508752102","article-title":"A schizophrenia-related sensorimotor deficit links alpha 3-containing GABAA receptors to a dopamine hyperfunction","volume":"102","author":"Yee","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.euroneuro.2008.07.002_bib54","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1055\/s-2004-827173","article-title":"Differential effects of long-term treatment with clozapine or haloperidol on GABA transporter expression","volume":"37","author":"Zink","year":"2004","journal-title":"Pharmacopsychiatry"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X08001739?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X08001739?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T20:27:31Z","timestamp":1684528051000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X08001739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["S0924977X08001739"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2008.07.002","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}